Skip to content

News Category: Health & Medical

Workforce Nutrition Alliance Publishes Booklet Highlighting Key Actions to Improve Workforce Nutrition

By asianet

– 11 Organisations Provide Examples, Learnings and Recommendations on How to Improve Nutrition at Work The Consumer Goods Forum (CGF) and the Global Alliance for Improved Nutrition (GAIN) ( https://www.gainhealth.org/ ), as part of the Workforce Nutrition Alliance (WNA) ( https://workforcenutrition.org/#/home ), are thrilled to publish the Workforce Nutrition Alliance Case Study Booklet ( https://tinyurl.com/2p94sjjd … Continued

Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK(R) (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

By asianet

Today, Medison Pharma (“Medison”), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, is pleased to announce the approval of KIMMTRAK(R) (tebentafusp) by Health Canada and Therapeutics Goods Administration (TGA) for the treatment of unresectable or metastatic uveal melanoma (mUM), a rare and aggressive form of melanoma … Continued

FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older

By asianet

–Novavax COVID-19 vaccine receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee –If Emergency Use Authorization is granted by the FDA, the Novavax COVID-19 vaccine would become the first protein-based COVID-19 vaccine available in the U.S. Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing … Continued

First Patient Enrolled in SELUTION SLR IDE BTK Study

By asianet

The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial involving SELUTION SLR(TM), MedAlliance’s novel sirolimus-eluting balloon, just one week after receiving IDE approval. “I am excited to begin an important trial which will establish the evidence that this novel technology benefit patients suffering from CLTI,” commented Dr. Michael Lichtenberg, … Continued

Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

By asianet

Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced the presentation at … Continued

Medison Pharma Announces Multi-Regional Partnership Agreement with argenx to Commercialize Efgartigimod Across Europe and Israel

By asianet

Medison Pharma [http://www.medisonpharma.com/] (“Medison”), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today an exclusive multi-regional agreement with argenx [https://www.argenx.com/] to commercialize efgartigimod in 14 countries, including Poland, Hungary, Slovenia, Czech Republic, Romania, Bulgaria, Lithuania, Croatia, Slovakia, Estonia, Latvia, Greece, Cyprus, and Israel, for the … Continued

CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer

By asianet

* The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy * Sugemalimab became the first anti-PD-1/PD-L1 monoclonal antibody approved for stage III NSCLC following concurrent or sequential chemoradiotherapy. It’s also the only anti-PD-(L)1 … Continued

Vazyme Releases 2021 Annual Report: Announces More Efforts in Technology innovation and Together with Partners for a Better Future

By asianet

Vazyme, China’s leading biotechnology company, has recently released its 2021 annual report, revealing that the company has maintained a steady and solid growth throughout the past year. The report shows that it has achieved $289 million in operating income with an increase of 19.44% year-on-year. The company’s R&D investment reached $36 million, up 83.47%, representing … Continued

Cambrex Acquires Leading EU Stability Storage Company Q1 Scientific

By asianet

Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced the acquisition of Q1 Scientific – a leading provider of environmentally-controlled cGMP stability storage services for the pharmaceutical, medical device and life science industries, strategically located in Waterford, Ireland. “Stability … Continued